Paranaense University-Praça Mascarenhas de Moraes, Umuarama, Paraná, Brazil.
Homeopathy. 2024 Feb;113(1):25-31. doi: 10.1055/s-0043-1768465. Epub 2023 Jul 5.
Bovine mastitis is characterized by an inflammatory process in the mammary gland and represents one of the main diseases affecting a dairy herd. Management of mastitis is most commonly via antibiotics, but the rising incidence of multiple antibiotic resistance (MAR) means that additional options are needed. Homeopathic products can be administered in dairy farming for a range of clinical reasons and may be preferential due to the absence of residues.
The aim of this study was to assess the potential of a novel homeopathic complex medicine in managing bovine mastitis.
Twenty-four lactating Holstein cows with mastitis were divided into two groups: the homeopathic complex group received a homeopathic complex daily for 60 days at a dose of 20 g/d; the placebo group received the calcium carbonate vehicle without homeopathic medicines at the same dose and repetition. The main outcome measure was somatic cell count (SCC; cells/mL), with additional outcome measures including milk production (kg/d), milk constituents (percentage of protein, fat, lactose and total milk solids), and serum levels of cortisol, glucose, ammonia and lactic acid. All outcomes were measured at the beginning of the study and after 30 and 60 days. Milk samples were also collected from all animals at the beginning of the study, confirming a high (>0.2) MAR index for isolated bacterial cultures.
Assessment of SCC showed a statistically significant difference favoring the homeopathic complex versus placebo group at day 60. A reduction in serum cortisol levels and an increase in fat, lactose and total milk solids in animals treated with the homeopathic complex at day 60 were also seen. Other outcome measures did not show statistically significant inter-group differences.
The results of this non-randomized, open-label, placebo-controlled trial suggest the potential for a novel homeopathic complex medicine in management of multiple antibiotic-resistant bovine mastitis, thus offering dairy farmers an additional option to antibiotics and making dairy products safer for consumer health and milk production more sustainable.
牛乳腺炎的特征是乳腺的炎症过程，是影响奶牛群的主要疾病之一。乳腺炎的治疗通常是通过抗生素，但由于多重抗生素耐药性（MAR）的发生率上升，需要额外的选择。顺势疗法产品可因多种临床原因在奶牛养殖中使用，并且由于不存在残留而可能更受青睐。
本研究旨在评估一种新型顺势疗法复方药物在治疗牛乳腺炎中的潜力。
将 24 头患有乳腺炎的泌乳荷斯坦奶牛分为两组：顺势疗法复方组每天接受一次新型顺势疗法复方治疗，为期 60 天，剂量为 20g/d；安慰剂组以相同剂量和重复剂量接受碳酸钙载体而无顺势疗法药物。主要观察指标是体细胞计数（SCC；细胞/ml），其他观察指标包括产奶量（kg/d）、乳成分（蛋白质、脂肪、乳糖和总乳固体的百分比）以及血清皮质醇、葡萄糖、氨和乳酸水平。所有结果均在研究开始时以及 30 天和 60 天时进行测量。所有动物在研究开始时还采集了牛奶样本，确认了分离细菌培养物的高（>0.2）MAR 指数。
SCC 的评估显示，在第 60 天时，顺势疗法复方组与安慰剂组之间具有统计学意义的差异。在第 60 天接受顺势疗法复方治疗的动物的血清皮质醇水平降低，脂肪、乳糖和总乳固体增加。其他观察指标未显示组间统计学差异。
这项非随机、开放标签、安慰剂对照试验的结果表明，一种新型顺势疗法复方药物在治疗多重抗生素耐药性牛乳腺炎方面具有潜力，为奶牛养殖户提供了抗生素以外的另一种选择，使乳制品更安全，有利于消费者健康，使牛奶生产更可持续。
